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Background
The development of new drugs for human Central Ner-
vous System (CNS) diseases has traditionally relied on
2D in vitro cell models and genetically engineered ani-
mal models. However, those models often diverge con-
siderably from that of human phenotype (anatomical,
developmental and biochemical differences) [1] contri-
buting to a high attrition rate - only 8% of CNS drugs
entering clinical trials end up being approved [2].
Human 3D in vitro models are useful complementary
tools towards more accurate evaluation of drug candi-
dates in pre-clinical stages, as they present an intermedi-
ate degree of complexity in terms of cell-cell and cell-
matrix interactions, between the traditional 2D mono-
layer culture conditions and the complex brain and can
be a better starting point for the analysis of the in vivo
context. Aiming at developing novel 3D in vitro models
of the CNS, this work focus on the implementation of
long-term cultures of human midbrain-derived neural
stem cells (hmNSC) for the scalable supply of neural-
subtype cells, with a focus on the dopaminergic lineage,
following a systematic technological approach based on
stirred culture systems.
Materials and methods
Cell culture: hmNSC were isolated as previously
reported [3] and routinely propagated in static condi-
tions, on poly-L-ornithine-fibronectin (PLOF) coated
plates, in serum-free propagation medium, containing
basic fibroblast growth factor and epidermal growth fac-
tor [3]. hmNSC were cultured in stirred systems in Cul-
tispher S microcarriers (Percell Biolytica) without
coating and coated with PLOF) or as neurospheres for 7
to 21 days, with media changes every 3-4 days. All
experiments were performed in 125 mL shake flasks (20
mL working volume), with orbital shaking at 100 rpm.
Cultures were maintained at 37°C, in 3% O2. Double
stain viability test: aggregates were collected from stirred
cultures, incubated with fluorescein diacetate (10 μg/
mL) and propidium iodide (1 μg/mL) and observed on a
fluorescence microscope (Leica DMI6000). Aggregate
size was measured in pictures taken from each culture
sample using Image J software (NIH), as previously
reported [4]. Dissociation: For microcarrier cultures,
Cultispher S was allowed to settle, washed with PBS and
digested with Trypsin 0.05%-EDTA (Gibco). Cells were
collected by centrifugation and counted by trypan blue
exclusion dye. Free cells were counted using the same
aliquot. Aggregates were dissociated with Accutase
(Sigma).
Results
The feasibility of culturing hmNSC as 3D structures in
stirred culture systems was assessed by testing two dif-
ferent approaches: microcarrier technology versus cell
aggregated cultures (neurospheres). For the first strategy,
Cultispher S, a collagen-based macroporous microcarrier
was tested for its ability to support hmNSC attachment
and growth. Microcarriers uncoated and coated with
PLOF were tested. hmNSCs were labelled with PKH26
lipophilic dye (red) for detection purposes and inocu-
lated at 1.5x10
5 cell/mL, in a carrier concentration of
1g/L, corresponding to approximately 125 cell/microcar-
rier. Monitoring along 5 days of culture time revealed
that the fraction of viable cells found on the microcar-
riers was less than 10% of the inoculum, for both
uncoated and PLOF-coated microcarriers, indicating
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analysis revealed that hmNSC aggregated in suspension
rather than colonizing Cultispher S microcarriers (not
shown). For the cell aggregate strategy, two inoculum
concentrations were tested - 2 and 4x10
5 cell/mL and
aggregate size and number evaluated along culture time
(Figure 1).
The inoculum concentration of 2x10
5 cell/mL was as
efficient as 4x10
5 cell/mL in promoting cell aggregation
(Figure 1A) whereas it allowed for lower mean dia-
meters along culture time (362±32 μm at day 14) as
compared to the higher inoculum concentration for
which significantly higher mean diameter and also a
wider range of aggregate sizes were observed (475±103
μm at day 14) (Figure 1B). Moreover, the lower inocu-
lum concentration avoided the formation of necrotic
centres, which were detected in cultures with an inocu-
lum concentration of 4x10
5 cell/mL (Figure 1C).Taken
together the data presented indicates that 2x10
5 cell/mL
is the most favourable inoculum concentration for cul-
ture of hmNSC as aggregates in stirred culture systems.
Conclusions
In this study the feasibility of culturing hmNSC as 3D
structures in stirred culture systems was evaluated. Cell
aggregates (neurosphere) culture, using an inoculum
concentration of 2x10
5 cell/mL was selected as the best
strategy, due to the higher cell viabilities and tightly
control of aggregate diameter attained. The implemen-
ted 3D culture system will be applied in the optimiza-
tion of differentiation of hmNSC into dopaminergic
neurons, astrocytes and oligodendrocytes.
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Figure 1 Effect of inoculum concentration on aggregate concentration (A), aggregate size (B) and viability (C), evaluated using a double stain
viability test: fluorescein diacetate (live, green); propidium iodide (dead, red). Cells were cultured in shake flasks with inoculum concentrations of
2 and 4x10
5 cell/mL. Error bars denote standard deviation of average of 3 independent experiments. *** indicates significant difference (P<0.001)
in aggregate diameter by one-way ANOVA analysis with a Tukey’s post-hoc multiple comparison test.
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